Paper Details

  1. Home
  2. Paper Details

Antineoplastic efficacy profiles of avapritinib and nintedanib in <i>KIT</i> D816V<sup>+</sup> systemic mastocytosis: a preclinical study.

Author: ArockMichel, BauerKarin, Degenfeld-SchonburgLina, EisenwortGregor, GamperlSusanne, GreinerGeorg, HadzijusufovicEmir, HoermannGregor, HoetzeneckerKonrad, JakschPeter, KopanjaSonja, PeterBarbara, ReiterAndreas, SadovnikIrina, SchruefAnna-Katharina, SchwaabJuliana, SmiljkovicDubravka, SperrWolfgang R, StefanzlGabriele, SzépfalusiZsolt, ValentPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examines the effects of two new drugs, avapritinib and nintedanib, on mast cells in systemic mastocytosis (SM). Both drugs inhibit the growth of mast cells, and avapritinib also inhibits mediator release, suggesting potential benefit for treating SM.
Paper Details　
Original Abstract of the Article :
Systemic mastocytosis (SM) is a hematopoietic neoplasm with a complex pathology and a variable clinical course. Clinical symptoms result from organ infiltration by mast cells (MC) and the effects of pro-inflammatory mediators released during MC activation. In SM, growth and survival of MC are trigge...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989615/

データ提供：米国国立医学図書館（NLM）

Avapritinib and Nintedanib: Fighting Systemic Mastocytosis with New Weapons

The complex and often unpredictable nature of systemic mastocytosis (SM), a rare disease caused by the overgrowth of mast cells, makes it a formidable foe for healthcare providers. This preclinical study investigated the potential of two novel drugs, avapritinib and nintedanib, in combating SM by targeting the aberrant KIT receptor, a key player in mast cell proliferation and survival. This research is akin to a desert warrior strategizing to conquer a formidable enemy, employing targeted tactics to suppress the disease's growth and spread. The study demonstrated that both avapritinib and nintedanib effectively inhibited the growth of neoplastic mast cells, showing promising potential as treatments for SM.

Harnessing the Power of Targeted Therapies

The study's findings highlight the power of targeted therapies in treating complex diseases like SM. By specifically targeting the aberrant KIT receptor, these drugs effectively combat the root cause of the disease. This approach is reminiscent of a skilled desert hunter tracking and eliminating a specific prey, minimizing collateral damage.

Hope for Systemic Mastocytosis Patients

The study provides a beacon of hope for individuals battling SM. The promising results of avapritinib and nintedanib offer potential for new treatment options and improved quality of life for patients.

Dr. Camel's Conclusion

This research underscores the continuous evolution of medicine in its quest to conquer even the most elusive diseases. Like the desert, which constantly shifts and transforms, the field of medicine is continually adapting and innovating to develop novel treatments that offer hope for patients struggling with complex and often debilitating conditions. The study's findings inspire us to continue pushing boundaries and discovering new ways to combat disease and enhance human health.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-11
Further Info :

Pubmed ID

36895976

DOI: Digital Object Identifier

PMC9989615

Related Literature

Article Analysis
・Effects of avapritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.